Scl-86, a marker antigen for XXXX .

@entity1 @entity9053 @entity3208 @entity95 @entity2631 @entity7087
More than 300 sera from @entity1 with a connective tissue disease were analyzed with the immunoblotting technique. The presence of autoantibodies against an 86,000-mol wt marker antigen for @entity7087 (Scl-86) was found in 14 out of 33 @entity1 with @entity2631 . The presence of anti-Scl-86 antibodies seemed to correlate with the diagnosis of @entity7087 since they were found in 13 out of 22 @entity7087 @entity1 and in only one out of 11 @entity1 with @entity9053 . All @entity2631 sera (33 @entity1 ' sera and 13 reference sera) were also tested for the presence of anti-Scl-70 antibodies. It was found that all anti-Scl-70 positive sera (n = 25) contained anti-Scl-86 antibody as well, suggesting a relationship between these two antigens. However, the Scl-86 antigen was shown to be an extremely insoluble nonchromosomal protein, resistant to boiling in @entity3208 . This contrasts with the Scl-70 antigen, which has been described as a thermolabile, soluble antigen present in the chromatin fraction. Together, our results are consistent with the idea that Scl-70 is a degradation product of Scl-86. The Scl-86 antigen is present in freshly prepared @entity95 thymus, spleen, and liver nuclei as well as in nuclei from various cultured cell lines, but is not detectable in extractable nuclear antigen from @entity95 thymus. In a limited retrospective study, the anti-Scl-86 antibodies were found in two sera from @entity1 with Raynaud's phenomenon before the development of @entity7087 . Therefore, it is possible that screening of patients' serum for this antibody might predict the development of @entity7087 .
